Study Finds Neurofeedback Improves ADHD Symptoms in Children

20 June 2022 by neurocare group

A collaborative study by the University of Wollongong and Peking University has recently demonstrated that Neurofeedback treatment improves symptoms, working memory and everyday functioning in children with Attention-deficit hyperactivity.

ADHD is one of the most common neurodevelopmental disorders in Australia with around 6-7% of children diagnosed with the disorder (Willcutt, E. G., 2012). Of those diagnosed, 65% continue to experience some symptoms into adulthood, with around 15% continuing to meet the full criteria of ADHD as adults (Ramtekkar et al., 2010).

Traditionally pharmacology has been used to reduce the symptoms of ADHD. While this can be an important component of treatment, not everyone improves with medication, and it can result in unhelpful side effects. As a result, there is increasing interest in non-pharmacological treatments. For those looking for to complement their medication, or for an alternative to medication, Neurofeedback is an effective and evidence-based approach for reducing the symptoms of ADHD .

Recent research findings

A 2022 peer-reviewed ADHD study published in European Child & Adolescent Psychiatry, has found that children with ADHD significantly improved their working memory, learning, and overall life skills through participation in neurofeedback training.

Researchers observed 80 children over a period of three months. Each child had been evaluated and diagnosed by a psychiatrist before taking part in the research. Throughout the treatment period, they completed three to five sessions of “gamified” Neurofeedback therapy per week, conducted remotely at home.

Researchers found a large improvement in ADHD symptoms at the end of the trial.

The study also verified the value of computerised, home-based treatment for ADHD, good news to busy families, those living in regional areas, and everyone seeking safe, socially distanced health care options.

This innovative study adds to a large body of scientific evidence demonstrating the effectiveness of Neurofeedback as a treatment for ADHD.

How Neurofeedback works

Neurofeedback relies on a gradual and natural learning process in the brain, like learning a musical instrument or sport. Once the new brain activity has been learnt, the positive effects can be sustained. Think of it like a “gym for the brain”.

Previous research has shown Neurofeedback has long lasting effects and the program can be completed in a short space of time, usually 2 – 3 months. The process rewards the brain for changing its activity, teaching the user to regulate their own mental states. Increased self-regulation corresponds with reductions in symptoms of ADHD and improvements in everyday functioning.

The neurocare approach

Neurocare adopts a personalised model to treatment that is:


The underlying causes of ADHD are not necessarily the same in two people. Because of this, we create therapy programs that look at the unique brain activity of each individual. neurocare clinicians use a QEEG assessment to map the unique patterns of brain behaviour underlying the symptoms you are experiencing. These EEG “brain maps” allow us to design a neurofeedback program specifically tailored to you.


At neurocare we recognise there are many different ways our mind can lose balance, so we adopt a personalised model of treatment. Using advanced assessment tools, to dig deeper, looking at brainwave activity to identify the root causes. We also consider biological, psychological and personal factors that are known to impact on your wellbeing, including sleep health and general cognitive function. Adopting a holistic approach allows us to develop a targeted and personalised therapy program to deliver optimal results.

Looking to complement your medication, or prefer an alternative to medication?

Contact us today to find out more about our treatments.



Ramtekkar, U. P., Reiersen, A. M., Todorov, A. A., & Todd, R. D. (2010). Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: Implications for DSM-V and ICD-11. Journal of the American Academy of Child & Adolescent Psychiatry, 49(3), 217-228. doi: http://dx.doi.org/10.1016/j.jaac.2009.11.011

Willcutt, E. G. (2012). The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics, 9(3), 490-499. doi: http://dx.doi.org/10.1007/s13311-012-0135-8

neurocare group

neurocare is a global brand in neuromodulation, active in research training in medication free applications of TMS and Neurofeedback for mental wellness. neuroCare operates therapy centers all over the world, with clinics now open across Sydney and Melbourne.

We integrate leading research, digital therapeutics, physical devices, clinics, and professional education to offer the most comprehensive mental health solutions to patients, therapists and the research community.

Visit our global website

neuroCademy Professional Training & Science



SPA Member Logo    

Copyright neurocare Group Pty Ltd. 2021. All rights reserved.